AYTU BioPharma, Inc. Common Stock (AYTU) — Analysis Summary
AYTU BioPharma, Inc. Common Stock (AYTU) has a market cap of $24.04M with year-over-year revenue growth of -18.0%. Net margin stands at -20.4%. The stock trades at a P/E ratio of -0.7.
Key Takeaways
- Revenue changed -18.0% year-over-year
- Net margin of -20.4%
- P/E ratio of -0.7
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, AYTU posted revenue growth of -18.0% and trades at a P/E of -0.7.
AYTU BioPharma, Inc. Common Stock (AYTU)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -6.8x — earnings do not cover interest payments
Operating margin at -26.8% — material operating losses
Net margin at -60.2% — significant losses
Revenue declined 14.7% vs the prior period.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
83
Headquarters
DENVER, CO
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.